Zydus Lifesciences Plans Semaglutide Launch Post Patent Expiry

MT Newswires Live02-26 14:52

Zydus Lifesciences (NSE:ZYDUSLIFE, BOM:532321) plans to launch Semaglutide injection under the brand names, SEMAGLYN, MASHEMA and ALTERM, following patent expiry in India, according to a company statement filed with the Indian bourses on Wednesday.

Shares of the company rose over 1% in Thursday's trade.

The Drug Controller General of India (DCGI) earlier approved the manufacturing and marketing of Semaglutide injection for the treatment of Type 2 diabetes mellitus and obesity, the statement said.

The company said its product will feature an indigenously developed drug-delivery system, including an adjustable single-pen device designed to deliver multiple approved dose strengths from one unit. The pen will be reusable and is intended to improve convenience and affordability.

Zydus holds exclusive rights to the device, which will cover all approved strengths for Type 2 Diabetes Mellitus and obesity, the statement said.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2614200091?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-26 14:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2614200091","market":"nz","top_or_hot":-1,"title":"Zydus Lifesciences Plans Semaglutide Launch Post Patent Expiry","media":"MT Newswires Live","content":"<html><body><p> Zydus Lifesciences (NSE:ZYDUSLIFE, BOM:532321) plans to launch Semaglutide injection under the brand names, SEMAGLYN, MASHEMA and ALTERM, following patent expiry in India, according to a company statement filed with the Indian bourses on Wednesday.</p><p>Shares of the company rose over 1% in Thursday's trade.</p><p>The Drug Controller General of India (DCGI) earlier approved the manufacturing and marketing of Semaglutide injection for the treatment of Type 2 diabetes mellitus and obesity, the statement said.</p><p>The company said its product will feature an indigenously developed drug-delivery system, including an adjustable single-pen device designed to deliver multiple approved dose strengths from one unit. The pen will be reusable and is intended to improve convenience and affordability.</p><p>Zydus holds exclusive rights to the device, which will cover all approved strengths for Type 2 Diabetes Mellitus and obesity, the statement said.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zydus Lifesciences Plans Semaglutide Launch Post Patent Expiry</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZydus Lifesciences Plans Semaglutide Launch Post Patent Expiry\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-02-26 14:52</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Zydus Lifesciences (NSE:ZYDUSLIFE, BOM:532321) plans to launch Semaglutide injection under the brand names, SEMAGLYN, MASHEMA and ALTERM, following patent expiry in India, according to a company statement filed with the Indian bourses on Wednesday.</p><p>Shares of the company rose over 1% in Thursday's trade.</p><p>The Drug Controller General of India (DCGI) earlier approved the manufacturing and marketing of Semaglutide injection for the treatment of Type 2 diabetes mellitus and obesity, the statement said.</p><p>The company said its product will feature an indigenously developed drug-delivery system, including an adjustable single-pen device designed to deliver multiple approved dose strengths from one unit. The pen will be reusable and is intended to improve convenience and affordability.</p><p>Zydus holds exclusive rights to the device, which will cover all approved strengths for Type 2 Diabetes Mellitus and obesity, the statement said.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4212","symbol_name":"包装食品与肉类","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2614200091","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2614200091","pubTimestamp":1772088726,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Zydus Lifesciences (NSE:ZYDUSLIFE, BOM:532321) plans to launch Semaglutide injection under the brand names, SEMAGLYN, MASHEMA and ALTERM, following patent expiry in India, according to a company state","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4212":"包装食品与肉类","POST":"Post Holdings"},"translate_title":"Zydus Lifesciences计划在专利到期后推出索马鲁肽","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"POST":1.5},"content_text":"Zydus Lifesciences (NSE:ZYDUSLIFE, BOM:532321) plans to launch Semaglutide injection under the brand names, SEMAGLYN, MASHEMA and ALTERM, following patent expiry in India, according to a company statement filed with the Indian bourses on Wednesday.Shares of the company rose over 1% in Thursday's trade.The Drug Controller General of India (DCGI) earlier approved the manufacturing and marketing of Semaglutide injection for the treatment of Type 2 diabetes mellitus and obesity, the statement said.The company said its product will feature an indigenously developed drug-delivery system, including an adjustable single-pen device designed to deliver multiple approved dose strengths from one unit. The pen will be reusable and is intended to improve convenience and affordability.Zydus holds exclusive rights to the device, which will cover all approved strengths for Type 2 Diabetes Mellitus and obesity, the statement said.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2614200091","isCrawlerRequest":true}